Trisubstituted Pyrazolopyrimidines as Novel Angiogenesis Inhibitors

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Weitensteiner, Sabine B ^a   Liebl, Johanna ^a   Krystof, Vladimir ^b   Havlíček, Libor ^c   Gucký, Tomáš ^b   Strnad, Miroslav ^b   Fürst, Robert ^a   Vollmar, Angelika M ^a   Zahler, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(2 AMINOCYCLOHEXYL)AMINO] 7 BENZYLAMINO 3 ISOPROPYL 1(2)H PYRAZOLO[4,3 D]PYRIMIDINE; 5 [(4 AMINOCYCLOHEXYL)AMINO] 7 BENZYLAMINO 3 ISOPROPYL 1(2)H PYRAZOLO[4,3 D]PYRIMIDINE; 7 (2 AMINOBENZYL)AMINO 5 [(2 AMINOCYCLOHEXYL)AMINO] 3 ISOPROPYL 1(2)H PYRAZOLO[4,3 D]PYRIMIDINE; 7 (2 AMINOBENZYL)AMINO 5 [(2 HYDROXYPROPYL)AMINO] 3 ISOPROPYL 1(2)H PYRAZOLO[4,3 D]PYRIMIDINE; 7 BENZYLAMINO 5 [(1 HYDROXYMETHYL)PROPYLAMINO] 3 ISOPROPYL 1(2)H PYRAZOLO[4,3 D]PYRIMIDINE; 7 BENZYLAMINO 5 [(2 HYDROXYPROPYL)AMINO] 3 ISOPROPYL 1(2)H PYRAZOLO[4,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 9; LGR 1404; LGR 1406; LGR 1407; LGR 1430; LGR 1667; LGR 1730; PYRAZOLOPYRIMIDINE DERIVATIVE; RAC1 PROTEIN; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; LAMELLIPODIUM; MICROVASCULAR ENDOTHELIAL CELL; MIGRATION INHIBITION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; CELL DEATH; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PROTEIN TRANSPORT; PSEUDOPODIA; PYRAZOLES; PYRIMIDINES; RAC1 GTP-BINDING PROTEIN;

EID: 84872398084     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054607     Document Type: Article

References (28)

1. Lamalice L, Le Boeuf F, Huot J, (2007) Endothelial cell migration during angiogenesis. Circ Res 100: 782-794.
2. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
3. Tonini T, Rossi F, Claudio PP, (2003) Molecular basis of angiogenesis and cancer. Oncogene 22: 6549-6556.
4. Carmeliet P, Jain RK, (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
5. Bergers G, Hanahan D, (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
6. Hellmich MR, Pant HC, Wada E, Battey JF, (1992) Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression. Proc Natl Acad Sci U S A 89: 10867-10871.
7. Songyang Z, Lu KP, Kwon YT, Tsai LH, Filhol O, et al. (1996) A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol 16: 6486-6493.
8. Smith DS, Tsai LH, (2002) Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol 12: 28-36.
9. Su SC, Tsai LH (2010) Cyclin-Dependent Kinases in Brain Development and Disease. Annu Rev Cell Dev Biol.
10. Liebl J, Furst R, Vollmar AM, Zahler S, (2011) Twice switched at birth: cell cycle-independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells. Cell Signal 23: 1698-1707.
11. Rosales JL, Lee KY, (2006) Extraneuronal roles of cyclin-dependent kinase 5. Bioessays 28: 1023-1034.
12. Meijer L, Raymond E, (2003) Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36: 417-425.
13. Aldoss IT, Tashi T, Ganti AK, (2009) Seliciclib in malignancies. Expert Opin Investig Drugs 18: 1957-1965.
14. Meijer L, Bettayeb K, Galons H (2006) (R)-Roscovitine (CYC202, Seliciclib). In: Smith PJ, Yue EW, editors. Inhibitors of cyclin dependent kinases as anti-tumor agents: CRC Press Taylor & Francis Group.
15. Liebl J, Weitensteiner SB, Vereb G, Takacs L, Furst R, et al. (2010) Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J Biol Chem 285: 35932-35943.
16. Berberich N, Uhl B, Joore J, Schmerwitz UK, Mayer BA, et al. (2011) Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9. Br J Pharmacol 163: 1086-1098.
17. Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, et al. (2006) Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 66: 7509-7515.
18. Tanaka T, Serneo FF, Tseng HC, Kulkarni AB, Tsai LH, et al. (2004) Cdk5 phosphorylation of doublecortin ser297 regulates its effect on neuronal migration. Neuron 41: 215-227.
19. Lilja L, Yang SN, Webb DL, Juntti-Berggren L, Berggren PO, et al. (2001) Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem 276: 34199-34205.
20. Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, et al. (1999) Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 19: 959-968.
21. Zahler S, Liebl J, Furst R, Vollmar AM, (2010) Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro. Angiogenesis 13: 239-249.
22. Krystof V, Rarova L, Liebl J, Zahler S, Jorda R, et al. (2011) The selective P-TEFb inhibitor CAN508 targets angiogenesis. Eur J Med Chem 46: 4289-4294.
23. Jorda R, Havlicek L, McNae IW, Walkinshaw MD, Voller J, et al. (2011) Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity. J Med Chem 54: 2980-2993.
24. Liebl J, Krystof V, Vereb G, Takacs L, Strnad M, et al. (2011) Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases. Angiogenesis 14: 281-291.
25. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, et al. (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243: 518-526.
26. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, et al. (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102: 463-468.
27. Rothmeier AS, Ischenko I, Joore J, Garczarczyk D, Furst R, et al. (2008) Investigation of the marine compound spongistatin 1 links the inhibition of PKC{alpha} translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J.
28. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, et al. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. JInvest Dermatol 99: 683-690.